TY - JOUR
T1 - Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria
AU - Finazzi, G.
AU - Carobbio, A.
AU - Thiele, J.
AU - Passamonti, F.
AU - Rumi, E.
AU - Ruggeri, M.
AU - Rodeghiero, F.
AU - Randi, M. L.
AU - Bertozzi, I.
AU - Vannucchi, A. M.
AU - Antonioli, E.
AU - Gisslinger, H.
AU - Buxhofer-Ausch, V.
AU - Gangat, N.
AU - Rambaldi, A.
AU - Tefferi, A.
AU - Barbui, T.
N1 - Funding Information:
Alessandro M Vanucchi at the University of Florence and investigators at the University of Pavia and at the Ospedali Riuniti di Bergamo were supported by a grant from Associazione Italiana per la Ricerca sul Cancro (AIRC, Milano) ‘Special Program Molecular Clinical Oncology 5 ⨯ 1000’ to AGIMM (AIRC-Gruppo Italiano Malattie Mieloproliferative).
PY - 2012/4
Y1 - 2012/4
N2 - In an international study of 1104 patients with essential thrombocythemia (ET), a histological review according to the 2008 World Health Organization (WHO) criteria confirmed ET in 891 patients (WHO-ET, 81%), and revised the diagnosis to prefibrotic primary myelofibrosis (PMF) in 180 patients (PMF, 16%). Major bleeding during follow-up occurred in 55 (6%) WHO-ET and 21 (12%) PMF patients (P=0.009), at a rate of 0.79 and 1.39% patients per year, respectively, (P=0.039). In a multivariable analysis, predictors of bleeding included diagnosis of PMF (P=0.05; hazard ratio (HR) 1.74), leukocytosis (P=0.04; HR 1.74), previous hemorrhage (P=0.025; HR 2.35) and aspirin therapy (P=0.001; HR 3.16). The analysis restricted to patients with WHO-ET confirmed previous hemorrhage (P=0.043; HR 1.92) and aspirin (P=0.027; HR 2.24) as independent risk factors. The current study reveals that major bleeding associated with thrombocytosis might be relatively specific to PMF, as opposed to WHO-defined ET. Furthermore, it shows that low-dose aspirin exacerbates these hemorrhagic events of PMF. In contrast, thrombocytosis per se was not a risk factor for bleeding; however, low-dose aspirin had a synergistic hemorrhagic effect unmasking the bleeding tendency of patients with extreme thrombocytosis. These observations carry significant therapeutic implications in these two WHO entities.
AB - In an international study of 1104 patients with essential thrombocythemia (ET), a histological review according to the 2008 World Health Organization (WHO) criteria confirmed ET in 891 patients (WHO-ET, 81%), and revised the diagnosis to prefibrotic primary myelofibrosis (PMF) in 180 patients (PMF, 16%). Major bleeding during follow-up occurred in 55 (6%) WHO-ET and 21 (12%) PMF patients (P=0.009), at a rate of 0.79 and 1.39% patients per year, respectively, (P=0.039). In a multivariable analysis, predictors of bleeding included diagnosis of PMF (P=0.05; hazard ratio (HR) 1.74), leukocytosis (P=0.04; HR 1.74), previous hemorrhage (P=0.025; HR 2.35) and aspirin therapy (P=0.001; HR 3.16). The analysis restricted to patients with WHO-ET confirmed previous hemorrhage (P=0.043; HR 1.92) and aspirin (P=0.027; HR 2.24) as independent risk factors. The current study reveals that major bleeding associated with thrombocytosis might be relatively specific to PMF, as opposed to WHO-defined ET. Furthermore, it shows that low-dose aspirin exacerbates these hemorrhagic events of PMF. In contrast, thrombocytosis per se was not a risk factor for bleeding; however, low-dose aspirin had a synergistic hemorrhagic effect unmasking the bleeding tendency of patients with extreme thrombocytosis. These observations carry significant therapeutic implications in these two WHO entities.
KW - aspirin
KW - bleeding
KW - essential thrombocythemia
KW - myeloproliferative neoplasms
KW - prefibrotic myelofibrosis
UR - http://www.scopus.com/inward/record.url?scp=84859650006&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859650006&partnerID=8YFLogxK
U2 - 10.1038/leu.2011.258
DO - 10.1038/leu.2011.258
M3 - Article
C2 - 21926959
AN - SCOPUS:84859650006
SN - 0887-6924
VL - 26
SP - 716
EP - 719
JO - Leukemia
JF - Leukemia
IS - 4
ER -